UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
September 26, 2007
------------
CRUCELL NV
(Exact name of registrant as specified in its charter)
P.O. BOX 2048 ARCHIMEDESWEG 4 2333 CN LEIDEN THE NETHERLANDS
(Address of principal executive offices)
000-30962
(Commission File Number)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
CRUCELL TO PRESENT PRE-CLINICAL RESULTS FOR H5N1 VIRUS TREATMENT
LEIDEN, THE NETHERLANDS, SEPTEMBER 14, 2007 - Dutch biotechnology company
Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that
its researchers have discovered a monoclonal antibody that is active against
H5N1 avian influenza. The studies will be presented at the 5th International
Bird Flu Summit scheduled for September 27 and 28 in Las Vegas, Nevada.
Crucell researchers produced antibodies in PERC6(R) cells and tested their
biophysical and immunological properties.
"Using phage display technology a set of human monoclonal antibodies active
against a broad range of distinct H5N1 strains was developed," said Crucell
Chief Scientific Officer Dr. Jaap Goudsmit. "We will show the ability of these
antibodies to prevent infection as well as to prevent and cure disease caused by
H5N1 virus in mice."
Crucell will provide more information about the research findings during the
two-day conference in Las Vegas.
ABOUT CRUCELL
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology
company focused on research, development and worldwide marketing of vaccines and
antibodies that prevent and treat infectious diseases. Its vaccines are sold in
public and private markets worldwide. Crucell's core portfolio includes a
vaccine against hepatitis B, a fully-liquid vaccine against five important
childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell
also markets travel vaccines, such as the only oral anti-typhoid vaccine, an
oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the
market. The Company has a broad development pipeline, with several Crucell
products based on its unique PER.C6(R) production technology. The Company
licenses this and other technologies to the biopharmaceutical industry.
Important partners and licensees include DSM Biologics, sanofi aventis, GSK and
Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with
subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company
employs over a 1000 people. For more information, please visit www.crucell.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements that involve inherent
risks and uncertainties. We have identified certain important factors that may
cause actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors please
refer to our Form 20-F, as filed with the U.S. Securities and Exchange
Commission on June 13, 2007, and the section entitled "Risk Factors". The
Company prepares its financial statements under generally accepted accounting
principles in the United States (US GAAP) and Europe (IFRS).
FOR FURTHER INFORMATION PLEASE CONTACT:
MEDIA: INVESTORS/ANALYSTS:
Barbara Mulder Oya Yavuz
Director Corporate Communications Director Investor Relations
Tel: 31-(0) 71 519 7346 Tel. +31-(0) 71-519 7064
press@crucell.com ir@crucell.com
www.crucell.com www.crucell.com
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
CRUCELL NV
-----------------------------------------
(Registrant)
September 26, 2007 /s/ LEON KRUIMER
- ------------------------ -----------------------------------------
(Date) Leon Kruimer
Chief Financial Officer